Feat: The future of digital in pharma; Drugs that track adherence; New medical device regulations; 2018's most important IP cases
What's next for digital in pharma?
Will drugs that track adherence when ingested be a tough pill for patients to swallow?
PharmaTimes presents Alantra’s annual look at the fastest-growing pharma companies
Following a meeting of the executive steering group, PharmaTimes Media is delighted to reveal the 2018 International Clinical Researcher of the Year finalists...
The PharmaTimes Communications Team of the Year competition is the only pharma industry award that tests the competencies and potential of communications agency teams, benchmarking talent agency side – and as such, entry is a must.
20th April 2018
With just 9 days to go until the prestigious PharmaTimes Clinical Researcher of the Year Awards Ceremony, the 2018 finalists are gearing up for their biggest challenge yet.
20th April 2018
Shire has now confirmed that it has thus far rejected three merger proposals from Takeda, the last one being valued at around $44 billion.
20th April 2018
As expected, an FDA advisory panel has backed approval of GW Pharmaceuticals/Greenwich Bioscience’s Epidiolex for treating seizures associated with Lennox-Gastaut syndrome and Dravet syndrome.
20th April 2018
AstraZeneca’s Tagrisso has been approved in the US as a first-line treatment for patients with metastatic non-small-cell lung cancer whose tumours have epidermal growth factor receptor (EGFR) mutations.
20th April 2018
Will the NHS giving more patients their own healthcare budgets result in inefficient spending or strengthen links between consumers and healthcare providers?
The promising global trends in vaccines
Keeping industry education up to speed means keeping things short
A look at the regulatory issues in genomic medicine that require further analysis
After having two of their children diagnosed with NP-C, Phil and Andrea Marella set up a charity to help find a cure for this devastating neurodegenerative disease
The industry veteran talks about how he’s helping to change drug discovery as chief business and strategy officer of the new Medicines Discovery Catapult
Will drugs that track adherence when ingested be a tough pill for patients to swallow?
For investors the future is bright, but it isn’t pharma
A look at some of the most important pharma IP cases from the past year and the rest of 2018
Pharma businesses need to prepare now for the EU’s sweeping regulatory changes to devices and in vitro diagnostics
How pharma should adapt to changes in the NHS that are impacting decision-making in primary care
How this Oxford spinout is using AI to tackle challenges in non-alcoholic fatty liver disease
This white paper will demonstrate that an investment in an instrument data system including validation can bring substantial business benefits to both a laboratory and its parent organisation
Medical Affairs professionals have a critical role to play – however, historically, it has been difficult for them to gain consistent access to critical data and analytics
Digitally-augmented multi-channel engagement has proved to be a useful approach for working with patients. However, it is easy for developers to default to a patient-facing website or an app that looks good and sounds impressive, but in practice doesn’t supply what patients want and need
PharmaMar is one of the few biopharmaceutical companies to have a product on the market, another awaiting commercialisation and various more at different stages of clinical development
Across all industries, people are changing the ways they engage with products, services, and brands. View more...
Wednesday, 28 September 2016 - 11:00 am
George Underwood
FREE - Listen again now - | VIEW NOW
